Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes
Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes
复制标题
DOI：
10.1159/000088948
复制
发表时间：
2006-01-01
期刊：
影响因子：
3.1
通讯作者：
Nakamura, N
中科院分区：
文献类型：
--
作者：
Ichida, Y;Hasegawa, G;Nakamura, N
抵抗素是一种新型的富含半胱氨酸的蛋白质，在胰岛素抵抗和动脉粥样硬化的发展中起作用。HMG-CoA还原酶抑制剂（他汀类药物）具有独立于其降脂作用的抗炎特性。本研究的目的是研究阿托伐他汀对体外表达的影响，并确定6个月的阿托伐他汀治疗对2型糖尿病患者血清中的β-淀粉样蛋白水平的影响。将3 T3-L1脂肪细胞和人单核细胞/巨噬细胞和前脂肪细胞与1和10 μ mol/l阿托伐他汀孵育24和48 h，然后通过定量实时逆转录-聚合酶链反应（qRT-PCR）测量cDNAn mRNA。在基线和阿托伐他汀治疗（10 mg/d）6个月后，测量2型糖尿病患者的血清谷氨酰胺浓度。qRT-PCR分析显示，阿托伐他汀以剂量和时间依赖性方式降低了p53 nmRNA的表达。阿托伐他汀治疗6个月后，血清谷氨酰胺浓度趋于降低，尽管这种降低没有达到统计学显著性。总之，我们的体外研究结果有助于他汀类药物的抗炎和抗动脉粥样硬化作用的证据越来越多，并使我们认为，他汀类药物可能通过抑制Escherichia coli mRNA的表达来控制炎症反应。有必要通过适当设计的大规模临床研究来确认我们体外研究的结果。版权所有（C）2006 S. Karger AG，巴塞尔。
Resistin is a novel cysteine-rich protein that plays a role in the development of insulin resistance and atherosclerosis. HMG-CoA reductase inhibitors (statins) possess anti-inflammatory properties that are independent of their lipid-lowering action. The aims of this study were to investigate the effect of atorvastatin on expression of resistin in vitro and to determine the effect of 6 months of treatment with atorvastatin on serum levels of resistin in patients with type 2 diabetes. 3T3-L1 adipocytes and human monocytes/macrophages and preadipocytes were incubated with 1 and 10 mu mol/l atorvastatin for 24 and 48 h, followed by measurement of resistin mRNA by the quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR). Serum resistin concentration in the patients with type 2 diabetes was measured at baseline and after 6 months of atorvastatin treatment (10 mg/day). qRT-PCR analysis revealed that atorvastatin decreased resistin mRNA expression in a dose- and time-dependent manner. Serum resistin concentration tended to decrease after 6 months of atorvastatin treatment, although this decrease did not reach statistical significance. In conclusion, the findings of our in vitro study contribute to the growing volume of evidence on the anti-inflammatory and anti-atherosclerotic effects of statins, and led us to suggest that statins may control inflammatory responses by inhibiting expression of resistin mRNA. It is necessary to confirm the findings of our in vitro study by an appropriately designed large-scale clinical study. Copyright (C) 2006 S. Karger AG, Basel.